Abstract
This paper addresses the fortunes of Biolyse, a small Canadian company, whose sole product for many years was an affordable version of the anticancer-drug, paclitaxel, derived from the yew tree. Repeated lawsuits and stringent regulations have made its survival precarious. The repeated attacks on this company demonstrate the travails of industrial innovation in confronting that other “crab” of big pharma. Sources include scientific publications, newspapers, interviews, and legal documents.
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
Jump to section
Related Articles
Cited By...
- No citing articles found.